A T Elvin
Overview
Explore the profile of A T Elvin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dimmitt D, Yu D, Elvin A, Giesing D, LANMAN R
Biopharm Drug Dispos
. 1991 Oct;
12(7):515-23.
PMID: 1932613
Multiple oral doses of diltiazem (DTZ) and propranolol (PPL, 60 mg every 8 h daily for 13 doses) were administered to 14 healthy volunteers alone and in combination on three...
2.
Yu D, Elvin A, Morrill B, Eichmeier L, LANMAN R, Lanman M, et al.
Clin Pharmacol Ther
. 1990 Jul;
48(1):26-33.
PMID: 2369807
Single doses of 1 gm 5-aminosalicylic acid (5-ASA) suspension was administered to 24 healthy volunteers during both fasting and fed conditions. For subjects in a fasting state, plasma 5-ASA and...
3.
Wagner J, Antal E, Elvin A, Gillespie W, PRATT E, Albert K
Biopharm Drug Dispos
. 1985 Jul;
6(3):341-3.
PMID: 4041560
No abstract available.
4.
Anderson G, Elvin A, Lalka D
J Pharm Sci
. 1984 Dec;
73(12):1791-3.
PMID: 6527258
Tris(2-butoxyethyl) phosphate (I), a plasticizer commonly found in evacuated blood collection tubes, displaces many basic drugs from their binding sites on serum proteins and causes them to redistribute from serum...
5.
Edwards D, Axelson J, Slaughter R, Elvin A, Lalka D
J Pharm Sci
. 1984 Sep;
73(9):1264-7.
PMID: 6491948
The free (unbound) concentration of drug in plasma is often an important determinant of pharmacological and toxicological effects. Unfortunately, studies examining the factors influencing the free fraction of quinidine in...
6.
Gipple K, Chan K, Elvin A, Lalka D, Axelson J
J Pharm Sci
. 1982 Sep;
71(9):1011-4.
PMID: 7131264
The metabolism of the antiarrhythmic drug tocainide (I) has been shown previously to occur via a novel pathway involving the addition of carbon dioxide to the primary amine nitrogen of...
7.
Elvin A, Axelson J, Lalka D
Br J Clin Pharmacol
. 1982 Jun;
13(6):872-4.
PMID: 6807333
No abstract available.
8.
Elvin A, Cole A, Pieper J, Rolbin S, Lalka D
Clin Pharmacol Ther
. 1981 Oct;
30(4):455-60.
PMID: 7285479
The effect of high-protein meal on the hepatic clearance (ClH) of intravenous lidocaine, because of its conceptual importance in understanding first-pass metabolic phenomena, was evaluated in nine healthy males. Our...
9.
Tocainide kinetics and metabolism: effects of phenobarbital and substrates of glucuronyl transferase
Elvin A, Lalka D, Stoeckel K, du Souich P, Axelson J, GOLDEN L, et al.
Clin Pharmacol Ther
. 1980 Nov;
28(5):652-8.
PMID: 6777107
Tocainide, a lidocaine congener with low hepatic clearance, is eliminated predominantly by formation of a novel glucuronide conjugate. This suggested the possibility of metabolic interactions with enzyme inducers or competitive...
10.
Elvin A, Keenaghan J, Byrnes E, Tenthorey P, McMaster P, Takman B, et al.
J Pharm Sci
. 1980 Jan;
69(1):47-9.
PMID: 7354440
The metabolism of tocainide, an experimental antiarrhythmic drug, was studied in humans. Urinary excretion of unchanged drug was 28-55% in 24 hr after oral dosing. Urine hydrolysis with hydrochloric acid...